The AHEAD-MERIT trial will take place in 15 hospitals, targeting patients with aggressive HPV-associated cancers with an innovative vaccine.
Gabriel Dumitrache
International
Foto: Shutterstock
Always see our news on Google
The AHEAD-MERIT clinical trial will take place in 15 hospitals in England, targeting patients with aggressive human papillomavirus (HPV)-associated cancers. These cancers have high rates of recurrence and poor survival. The vaccine being developed targets proteins commonly found in HPV-associated head and neck cancer. The health secretary declared the initiative a "huge victory" and NHS England is working with BioNTech to identify eligible patients. This is the third trial under the NHS Cancer Vaccine Launch Pad, which has already supported 550 patients.
Sources
Latest News
09:41
An earthquake with a magnitude of 5.5 shook El Salvador, Honduras, and Nicaragua on Wednesday, without causing casualties or damage.
09:27
Possible drone fragment, observed off the coast, in the Costinești area. Authorities are currently intervening on site.
09:07
The Danube's flow at the entrance to Romania remains stable, below the multiannual average for the month of August. Hydrologists estimate a slight increase in the next 24 hours.
08:55
Volodymyr Zelensky, interview for CNN: "If the USA sells us 10% of the Patriot missiles, we will destroy all Russian ballistic missiles"
08:50
Russian attack on the port of Izmail, near the border with Romania. The port infrastructure was engulfed in flames.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
